The Lupus Foundation of America (LFA) celebrated exceptional lupus researchers at the 20th Anniversary Evelyn V. Hess ...

The new guidelines include three strong recommendations: Universal treatment with hydroxychloroquine (absent ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...

There are multiple chapters near you. Select your preferred chapter.

In a new study, researchers found people with clinically active systemic lupus erythematosus (SLE) disease on standard of care can attain or achieve low disease activity (LLDAS) and meet the ...

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...

AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus erythematosus met its primary endpoint. Trial results showed that ...

A new study found that both lupus anticoagulant (LA) and anti-β2 glycoprotein I (β2GPI) IgG/IgM antibodies had predictive value for adverse pregnancy outcomes and complications, specifically ...

In a new study, systemic lupus erythematosus (SLE) disease severity indicated by the presence of lupus nephritis, (LN, lupus-related kidney disease) and other SLE risk factors contributed to reduced ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Host 0:04 Welcome to The Expert Series brought ...